Showing 4411-4420 of 5957 results for "".
- Genentech Voluntarily Recalls Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-voluntarily-recalls-susvimo-ocular-implant-for-wet-amd/2481185/Roche and Genentech announced a voluntarily recall of the Susvimo (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. In addition, the companies announced that new implantations, including in ongoing global clinical trials, have been paused.
- Lori Tierney Joins Johnson & Johnson Vision as President of Americashttps://modernod.com/news/lori-tierney-joins-johnson-johnson-vision-as-president-of-americas/2481184/Johnson & Johnson Vision announced that Lori Tierney has joined the company as President of Americas. In this critical leadership role, Ms. Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme
- Olleyes Announces Partnership With Tobii to Incorporate Advanced Eye Tracking Features Into VisuALL ETS Modelhttps://modernod.com/news/olleyes-announces-partnership-with-tobii-to-incorporate-advanced-eye-tracking-features-into-visuall-ets-model/2481178/Olleyes announces a partnership with Tobii to incorporate advanced eye tracking features within the VisuALL Virtual Reality Platform (VRP) ETS package. Tobii technology will further enhance the capabilities of the Olleyes VisuALL ETS to deliver a variety of ophthalmic tests with superior acc
- Oculis SA and European Biotech Acquisition Corp Announce Agreement to Create Nasdaq-Listed Biopharmaceutical Companyhttps://modernod.com/news/oculis-sa-and-european-biotech-acquisition-corp-announce-agreement-to-create-nasdaq-listed-biopharmaceutical-company/2481177/Oculis SA and European Biotech Acquisition Corp (EBAC) announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis&rsqu
- Investigational Optejet Microdose Dispenser From Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia, and Patients Getting Eye Examshttps://modernod.com/news/investigational-optejet-microdose-dispenser-from-eyenovia-shows-promise-in-improving-treatment-for-myopia-presbyopia-and-patients-getting-eye-exams/2481176/Two recent studies show that the Optejet dispenser from Eyenovia may be a more "human-centric" design than traditional eye droppers, which may make treatments for vision problems, including myopia, presbyopia, and mydriasis easier to deliver, according to Eyenovia.
- PatientPoint Acquires Rendia to Accelerate Expansion into Ophthalmology Specialtyhttps://modernod.com/news/patientpoint-acquires-rendia-to-accelerate-expansion-into-ophthalmology-specialty/2481166/PatientPoint announced the acquisition of Rendia, a provider of point-of-care content for eye care providers sold on a subscription basis. Terms of the deal were not disclosed. With PatientPoint’s expansion into ophthalmology and optometry, PatientPoint’
- TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for Glaucoma Drug Candidate TC-002https://modernod.com/news/tearclear-announces-positive-topline-results-from-clear-phase-3-study-for-the-treatment-of-glaucoma-with-tc-002-latanoprost-ophthalmic-solution-0005/2481165/TearClear announced that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR phase 3 pivotal trial. With these results, TearClear plans to file a new drug application (NDA) with the FDA in
- Researchers Discover New Molecular Driver of Retinoblastomahttps://modernod.com/news/researchers-discover-new-molecular-driver-of-retinoblastoma/2481163/Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Now researchers at UT Southwestern and the University of Miami have <
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c